Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. (Q39283394)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Jon Kroll Bjerregaard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Per Pfeiffer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Benny Vittrup Jensen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Trine Lembrecht Jorgensen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Dorte Nielsen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

1 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

833-836

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Current role of antibody therapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.482104

10.3109/0284186X.2010.482104

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615171%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference